The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
3,4-bis(benzyloxy)furan-2,5-dicarboxylic acid ID: ALA2261214
PubChem CID: 2801517
Max Phase: Preclinical
Molecular Formula: C20H16O7
Molecular Weight: 368.34
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: O=C(O)c1oc(C(=O)O)c(OCc2ccccc2)c1OCc1ccccc1
Standard InChI: InChI=1S/C20H16O7/c21-19(22)17-15(25-11-13-7-3-1-4-8-13)16(18(27-17)20(23)24)26-12-14-9-5-2-6-10-14/h1-10H,11-12H2,(H,21,22)(H,23,24)
Standard InChI Key: ZHFHXTPKRGXQSE-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 29 0 0 0 0 0 0 0 0999 V2000
14.1162 -11.5296 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.7769 -12.0237 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
15.4508 -11.5457 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.2019 -10.7592 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3782 -10.7494 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.6344 -10.0586 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
13.9035 -10.0795 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
16.4595 -10.0792 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.8919 -9.3743 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.7152 -9.3998 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.1435 -8.6959 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.7507 -7.9694 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9214 -7.9514 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4927 -8.6561 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.0783 -10.0691 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.6725 -9.3486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.0959 -8.6416 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.6909 -7.9217 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.8647 -7.9108 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.4453 -8.6259 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.8486 -9.3431 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.2772 -11.5665 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.6691 -12.2924 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
16.7062 -10.8663 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
13.3877 -11.9256 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.6834 -11.4923 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
13.3660 -12.7507 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
3 4 2 0
4 5 1 0
5 1 2 0
4 6 1 0
5 7 1 0
6 8 1 0
8 9 1 0
9 10 2 0
10 11 1 0
11 12 2 0
12 13 1 0
13 14 2 0
14 9 1 0
7 15 1 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 16 1 0
22 23 1 0
22 24 2 0
3 22 1 0
25 26 1 0
25 27 2 0
1 25 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 368.34Molecular Weight (Monoisotopic): 368.0896AlogP: 3.83#Rotatable Bonds: 8Polar Surface Area: 106.20Molecular Species: ACIDHBA: 5HBD: 2#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 3.47CX Basic pKa: ┄CX LogP: 3.40CX LogD: -3.07Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.62Np Likeness Score: -0.10
References 1. Magesh S, Moriya S, Suzuki T, Miyagi T, Ishida H, Kiso M. (2010) Use of structure-based virtual screening in the investigation of novel human sialidase inhibitors, 19 (9): [10.1007/s00044-009-9269-6 ]